Rathbones Group’s GSK GSK Stock Holding History

Rathbones Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$253K	Hold	4,580	–	–	﹤0.01%	546
2025 Q4	$225K	Sell	4,580 -6,500	-59%	-$303K	﹤0.01%	561
2025 Q3	$478K	Buy	11,080 +2,904	+36%	+$113K	﹤0.01%	448
2025 Q2	$314K	Hold	8,176	–	–	﹤0.01%	493
2025 Q1	$316K	Hold	8,176	–	–	﹤0.01%	459
2024 Q4	$276K	Hold	8,176	–	–	﹤0.01%	483
2024 Q3	$334K	Hold	8,176	–	–	﹤0.01%	463
2024 Q2	$315K	Hold	8,176	–	–	﹤0.01%	475
2024 Q1	$351K	Sell	8,176 -728	-8%	-$30K	﹤0.01%	462
2023 Q4	$330K	Hold	8,904	–	–	﹤0.01%	460
2023 Q3	$323K	Buy	8,904 +1,044	+13%	+$37.1K	﹤0.01%	464
2023 Q2	$280K	Hold	7,860	–	–	﹤0.01%	343
2023 Q1	$280K	Hold	7,860	–	–	﹤0.01%	350
2022 Q4	$276K	Buy	+7,860	New	+$262K	﹤0.01%	347
2021 Q2	–	Sell	-4,660	Closed	-$208K	–	429
2021 Q1	$208K	Sell	4,660 -720	-13%	-$32.7K	﹤0.01%	374
2020 Q4	$247K	Hold	5,380	–	–	﹤0.01%	346
2020 Q3	$253K	Hold	5,380	–	–	﹤0.01%	325
2020 Q2	$274K	Sell	5,380 -121	-2%	-$6.21K	0.01%	300
2020 Q1	$261K	Hold	5,501	–	–	0.01%	260
2019 Q4	$323K	Hold	5,501	–	–	0.01%	267
2019 Q3	$293K	Hold	5,501	–	–	0.01%	279
2019 Q2	$275K	Hold	5,501	–	–	0.01%	273
2019 Q1	$287K	Hold	5,501	–	–	0.01%	265
2018 Q4	$263K	Hold	5,501	–	–	0.01%	267
2018 Q3	$276K	Hold	5,501	–	–	0.01%	259
2018 Q2	$277K	Hold	5,501	–	–	0.01%	250
2018 Q1	$269K	Sell	5,501 -640	-10%	-$29.8K	0.01%	257
2017 Q4	$272K	Sell	6,141 -1,360	-18%	-$62.8K	0.01%	265
2017 Q3	$381K	Hold	7,501	–	–	0.02%	227
2017 Q2	$404K	Hold	7,501	–	–	0.02%	227
2017 Q1	$395K	Sell	7,501 -1,960	-21%	-$99.4K	0.02%	228
2016 Q4	$455K	Buy	9,461 +2,400	+34%	+$119K	0.02%	212
2016 Q3	$381K	Hold	7,061	–	–	0.02%	224
2016 Q2	$383K	Hold	7,061	–	–	0.02%	216
2016 Q1	$358K	Sell	7,061 -273	-4%	-$13.6K	0.02%	217
2015 Q4	$369K	Hold	7,334	–	–	0.02%	216
2015 Q3	$352K	Hold	7,334	–	–	0.02%	221
2015 Q2	$382K	Hold	7,334	–	–	0.02%	228
2015 Q1	$423K	Sell	7,334 -2,871	-28%	-$165K	0.03%	220
2014 Q4	$545K	Sell	10,205 -312	-3%	-$17.5K	0.04%	202
2014 Q3	$604K	Buy	10,517 +240	+2%	+$14.7K	0.04%	187
2014 Q2	$687K	Buy	10,277 +934	+10%	+$63.2K	0.05%	178
2014 Q1	$624K	Buy	9,343 +1,136	+14%	+$76.8K	0.05%	176
2013 Q4	$548K	Sell	8,207 -1,800	-18%	-$117K	0.05%	157
2013 Q3	$628K	Hold	10,007	–	–	0.07%	152
2013 Q2	$625K	Buy	+10,007	New	+$635K	0.08%	134

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Rathbones Group's GSK Position: Q1 2026 in Review

Rathbones Group held its GSK (GSK) position steady in Q1 2026 at 4,580 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #546.

Rathbones Group first reported a position in GSK in Q2 2013 and has held it in 46 quarters since. The position peaked at $687K in Q2 2014. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Rathbones Group held 4,580 shares of GSK worth $253K as of Q1 2026.
Rathbones Group left its GSK share count unchanged in Q1 2026.
GSK made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #546 holding.
Rathbones Group first reported a position in GSK in Q2 2013 and has held it in 46 quarters since.
Rathbones Group's GSK position peaked at $687K in Q2 2014.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.